Treprostinil dry powder - Liquidia Technologies
Alternative Names: LIQ-861; YUTREPIALatest Information Update: 20 Mar 2024
At a glance
- Originator Liquidia Technologies
- Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Pulmonary arterial hypertension
Most Recent Events
- 12 Mar 2024 The Federal Circuit rejects request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid
- 25 Jan 2024 The US FDA is unable to issue an action letter on PDUFA date of January 24, 2024 and continues the NDA review for treprostinil dry powder for pulmonary hypertension associated with interstitial lung disease (PH-ILD)
- 20 Dec 2023 US Federal Circuit affirms earlier Patent Trial and Appeal Board (PTAB) decision to invalidate all claims of United Therapeutics Patent No.10,716,793 ('793 Patent)